Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment

Four with Medical School ties are among 12 University of Michigan faculty and staff members recognized by the American Association for the Advancement of Science (AAAS) as 2023 fellows in recognition of their extraordinary achievements.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

2 in 3 parents in national poll say their child ages 5-12 use personal audio devices; pediatrician offers 4 tips to reduce noise exposure risks

Using a chip to process blood samples, doctors can monitor the amount of cancer cells in a patient’s blood to determine how well a treatment is working by the fourth week, according to a new study.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

A Michigan Medicine expert explains more of a report’s key findings on cell phone use and how parents can support a healthy use of technology.

Michigan Medicine research tracks academic trajectories of late preterm infants from infancy to kindergarten and identifies developmental risks and how to best promote resilience

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.

There are 13 U-M graduate medical education programs ranked in the top 10 by Doximity.